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Antimicrobial peptides (AMPs) represent a group of small (6–100 amino acids), biologi-
cally active molecules, which are produced by plants, mammals, and microorganisms (1).
An important element of the innate immune response, AMP, possesses potent antibi-
otic, antifungal, and antiviral activities. Furthermore, AMP may be involved in a number of
other processes such as angiogenesis and modulation of the immune response such as
stimulation of chemokines and chemotaxis of leukocytes. AMPs have been proposed as
alternative therapies for infectious diseases. AMP may also exert cytotoxic activity against
tumor cells. Further understanding of the biological function of these peptides during tumor
development and progression may aid in the development of novel anti-tumor therapies
with refined application of innate molecules. AMP and complement have distinct roles to
play in shaping the microenvironment (Table 1). Components of the complement system
are integral contributors in responding to infection and sterile inflammation. Moreover, com-
plement plays a role in the trafficking of cells in the tumor microenvironment, and thereby
possibly in the immune response to cancer. This article will try to outline characteristics of
AMP and complement in mobilization and recruitment of cells in tumor microenvironment.
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DEFENSINS, AN EXAMPLE OF ANTIMICROBIAL PEPTIDES
WITH A CONTROVERSIAL ROLE IN CANCER
The defensin family includes three subfamilies (α, β, and θ
defensins). Defensins can be stored in cytoplasmic granules of
neutrophils and in macrophages or can be released into the extra-
cellular environment from epithelial cells and mesothelial cells. In
humans, there are 6 α defensins and 11 β defensins, exhibiting a
wide range of antimicrobial, but also additional biological activ-
ities: β defensins possess a proinflammatory effect via binding a
variety of receptors. For example, human β defensin 2 (hBD-2)
and, to a lesser extent, human β defensin 1 (hBD1) bind to CCR6
resulting in increased chemoattraction of both CD4+ memory T
cells and immature dendritic cells (2). β defensins can also play a
role in tumorigenesis. Altered expression of β defensins was seen
in epithelial cell-derived cancers such as prostatic cancer, basal
cell carcinoma, oral squamous cell carcinoma (OSCC) and renal
cell carcinoma. Expression of hBD1 was found to be diminished
or suppressed in malignant prostate tissue compared to high or
moderate expression of hBD1 in surrounding benign tissue (3).
This altered expression of β defensins led researchers to investigate
anti-tumor activity of β defensins. Results showed that induction
of hBD1 expression in prostatic cancer cell line lead to increased
cell death inferring that hBD1 is anti-tumorigenic and that loss
or decrease in expression may lead to tumor progression. In this
sense, it was found that diminished expression of hBD1 was found
associated with worse grading of prostate cancer (4).
However, the role of defensins in tumor development and
tumor progression has been controversial with some groups
reporting overexpression of some β defensins in some types of
cancer. High levels of hBD1 and hBD-2 were found in sera of
patients with lung cancer. Another example is the overexpression
of hBD1 in renal cell carcinoma and hBD3 in OSCC (5, 6).
Further investigation into the role of hBD3 in mediating the
tumor-related inflammatory process in oral cancer revealed that
overexpression of hBD3 was associated with recruitment and
accumulation of tumor-associated macrophages (TAM). These
cells represent a significant part of infiltrating immune cells in
the tumor microenvironment and are thought to play a role
in the development and progression of tumors, but are prob-
ably a heterogeneous population (7). Moreover, hBD3 overex-
pression stimulated the expression of interleukin-1α (IL-1α), IL-
6, IL-8, CCL18, and tumor necrosis factor-α (TNF-α). HBD3
chemoattract monocytes to the tumor microenvironment via
chemokine receptor 2 (CCR2), further supporting the role of
human β defensins in establishing the tumor microenvironment,
which leads to tumor progression (8). By increasing vascular-
ization, HBD increase tumor angiogenesis in SCC microenvi-
ronment (9). Conejo-Garcia and coworkers described a mecha-
nism in which β defensins support tumor vasculogenesis through
recruitment of dendritic cell precursors. Tumor vascularization
and growth were enhanced in the presence of increased Vegf-A
expression (10).
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Table 1 |Tumors develop a complex network of cellular interactions involving both proinflammatory and suppressive cells.
Immunosuppressive Proinflammatory
C5a/C5aR→MDSC recruitment C5a attract CD8+ T-cells
AMP involved in angiogenesis AMP exert cytotoxic activity
↓ Expression of human β defensin 1→ tumor progression
(prostate cancer)
↑ hBD3 associate with recruitment TAM (lung cancer, renal cell carcinoma,
and OSCC)
HPN1 inhibition Classical and Lectin pathway β defensins bind to a variety of receptors (CCR2)
Express α defensins (HPN1-3) in endothelial→ angiogenesis hBD1 bind to CCR6 resulting in ↑ CD4+
Express α defensins (HPN1-3) in endothelial→ angiogenesis Blockage of C5aR ↓ decrease tumor growth
Deficiency of LL37aid in inflammation and tumor progression Overexpression hBD3→ chemoattract monocytes tumor microenvironment
↑ ↑↑ HPN1-3→ cytotoxic effect on cancer cell line
It was also found that HBD3 has the ability to inhibit the migra-
tion of colon cancer cells in a dose-dependent manner, which
means that HBD3 could be a potential new drug for treatment of
colon cancer (11).
Other reported activities of defensins include activation of
the classical pathway of complement. The interaction with the
complement system occurs via both C1q-dependent and C1q-
independent mechanisms (12, 13). In contrast, other studies have
reported that HBD-2, which has a structural homology with a C1q
inhibitory molecule, can significantly inhibit the classical pathway
of complement (14). Some defensins may inhibit both the classical
and lectin pathways of complement. Human neutrophilic peptide
1 (HPN1) was found to bind to C1q and MBL leading to inhibition
of these two complement activation pathways (15).
Human β defensins have not been the only group of defensins
associated with tumor tissue. In the last few years, α defensins
were detected in malignant tissue and fluids (serum and plasma)
from patients with cancer. Human neutrophilic peptides 1, 2, and
3 (HNP 1–3), members of α defensins antimicrobial peptides
(AMP), are expressed in endothelial cells in several tumor types
suggesting that angiogenesis could be effected by α-defensins (16).
The role of α defensins in cancer has also been controversial with
some in vitro studies suggesting that supranormal (>25µg/ml)
levels of HNP1–3 have a cytotoxic effect on cancer cell lines and
physiologic levels (6–25µg/ml) of HNP 1–3 increase the prolifer-
ation and invasiveness of cancer cell lines (17), while others show
that α defensin expression associates with greater invasiveness
in vivo and in vitro (18).
COMPLEMENT AND CANCER
The complement system is an important element of the innate
immunity with a well-established role in acute inflammation
and continuous activation in chronic inflammation. In addition,
components of the complement system mediate cellular regener-
ation and growth (bone and cartilage development, neurogenesis,
bone marrow engraftment and regeneration of the liver) (19, 20).
The complement activated system play a dual role in the tumor
microenvironment. Traditionally, it was assumed that components
of the complement system play a role in anti-tumor immune
response either through complement mediated cytotoxicity or via
antibody-dependent cell-mediated cytotoxicity. However, work
has suggested that components of the complement system may
also cause immune suppression and enhance tumor growth which
means that the role of complement components in tumor growth
should be revisited. Complement anaphylatoxins C3a and C5a
play a complex role in tumor growth by inhibit antigen-specific
CD8+ T cell-mediated anti-tumor immune responses. In their
study of a murine TC-1 syngeneic model of cervical cancer, block-
age of C5aR resulted in decreased tumor growth. Coinciding with
an increase in infiltrating CD8+ cytotoxic T cells and inhibition
of MDSC recruitment (21), the effect of C5aR blockade was sim-
ilar to that seen after treatment with a well-known anti-tumor
chemotherapeutic agent. Moreover, a similar degree of inhibition
in tumor growth was also noted in C5aR-deficient mice. MDSCs
isolated from C5aR-deficient tumor bearing mice lacked the abil-
ity to inhibit CD3+ T cells proliferation seen in C5aR wild-type
mice (21). Overactivation of the infiltrating cells due to high con-
centration of C5a may result in suppression of anti-tumor T cells,
thus leading to progression of tumors. On the other hand, low
concentration of C5a can lead to a powerful anti-tumor immune
response (22).
These findings present complement inhibition as an option
for developing novel anti-cancer therapies, which lacks the side
effects of the conventional anti-cancer therapies. The concomitant
inhibition of egress of cells from the bone marrow by interfering
with C5a/C5aR interactions, however, carries a possible risk of
compromised inflammatory response to infection.
C3 deficiency leads to altered immune response in experimen-
tal ovarian cancer causing a decrease in tumor development and
progression (23).
CATHELICIDINS, A GROUP OF ANTIMICROBIAL PEPTIDES
WITH MISCELLANEOUS BIOLOGICAL FUNCTIONS
Cathelicidins constitute a mammalian antimicrobial peptide fam-
ily. Cathelicidins are characterized by a variable antimicrobial pep-
tide on the C-terminus and a moderately conserved N-terminal
cathelin domain. The cationic property of cathelicidin enables it to
electrostatically react with the anionic membrane of microbes and
some tumor cells resulting in disruption of cell membranes, which
eventually leads to cell death. This process results in destruction
of tumor cells (and microbes), while normal cells are left intact. In
humans, the only known cathelicidin is the hCAP-18/LL37. After
stimulation, hCAP-18 is cleaved producing a peptide containing 37
amino acids starting with two leucines termed LL37. Expression of
the hCAP-18 gene was found in squamous epithelium of intestine,
mouth, cervix, tongue, esophagus, and the airways. In addition,
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LL37 is produced by immature neutrophils, natural killer cells, B
cells, monocytes, and mast cells. LL37 plays a protective role in
preventing bacterial inflammations. This conclusion came from
the observation that LL37 is down regulated in patients infected
with Shigella. A number of studies have pointed out that catheli-
cidin could play an important role in preventing bacteria-related
inflammation and perhaps also carcinogenesis. An example of this
is infection of the gut with Helicobacter pylori, where LL37 is over-
expressed in the early stages of infection providing a protective
role. However, the expression of LL37 is reduced as the infec-
tion progresses and results in disturbances in cell turnover in the
gastrointestinal tract contributing to H. pylori-associated carcino-
genesis in the GI tract. Promotion of carcinogenesis and inflam-
mation is attributed to dysregulation of cathelicidin (mechanism
unknown). Collectively, these findings suggest that deficiency in
this peptide may aid in inflammation and tumor progression (24).
So what is the precise role of these AMP during inflammation
and carcinogenesis? In addition to its antimicrobial ability, LL37
seems to have a chemotactic capability facilitating the migration
of neutrophils, monocytes, CD4+ cells, and mast cells. LL37 also
has the ability to induce degranulation and release of inflamma-
tory mediators from mast cells, which are one of the first immune
cells that encounter invading microbes. It has been suggested that
LL37 augments the host’s immune response via regulation of the
expression of particular genes with anti-inflammatory and proin-
flammatory roles (25). In addition, LL37 enhances the induction
phase of adaptive immunity through recruitment of T helper cells
and increased HLA-DR expression by human dendritic cells (26).
Thus, Cathelicidins seem to have a role in augmenting both innate
host defenses and adaptive immunity and, where activity is high,
may aid in establishing an anti-tumor response.
Defining the exact role that LL37 plays during carcinogene-
sis is not straight forward. In some studies, expression of LL37
was found to increase in a number of tumors such as ovarian,
lung, and breast cancers. On the other hand, the same peptide was
found to possess a suppressive role in other types of cancers such
as GI tract cancer. This observation was further supported by the
finding that Cathelicidin-deficient mice had increased suscepti-
bility to carcinogen-induced colonic tumors. Further studies have
shown that LL37 exerts an apoptogenic function via a caspase-
independent manner (27). Furthermore, it was shown that lung
tumor growth is promoted by cathelicidin expressed in tumor
cells (28).
The role that LL37 plays during carcinogenesis might be related
to whether the cancer is the result of persistent inflammation or if
the inflammation is a result of cancer.
THE ANTI-TUMORAL ACTIVITY OF SOME AMP AND
COMPLEMENT COMPONENTS AGAINST HEMATOLOGICAL
TUMORS
Hematological tumors such as leukemias and lymphomas cause
approximately 10% of deaths in cancer patients. Thus, there is
a demand to develop new anti-tumoral agents preferably from
natural and biological sources, which targets tumor cells. In addi-
tion to their antimicrobial properties, some AMPs seem to exert a
cytotoxic effect against tumor cells. Recent studies have focused on
exploring the anti-tumoral activity of some AMPs and presenting
them either as alternatives to conventional anti-tumor therapies
or to be used in combination with other conventional anti-tumor
drugs. It is thought that the anti-tumoral activity of these pep-
tides occurs mainly via apoptosis and necrosis. However, the exact
mechanism by which some AMPs exert their anti-tumoral activity
is not fully understood yet. There have been many speculations in
this regard; one of the suggestions is that cell death of tumor cells
is due to a detergent-like effect and cell permeabilization. On the
other hand, one group has demonstrated that tumor cell death may
be a result of calcium accumulation in the mitochondria. It has
also been proposed that the anti-tumoral activity of some AMP
is a result of the cationic nature of most of these peptides. It is
thought that the selective killing of tumor cells is the end result of
an interaction between the cationic peptides and the anionic cell
membrane components. Certain AMPs can be used with conven-
tional chemotherapeutic drugs to enhance their cytotoxic activity.
An example of such AMPs is Cecropin A (CA), which has a cyto-
toxic effect on human lymphoblastic leukemia and can be used as
a pharmacological tool with some chemotherapeutic drugs such
as CA/S–FU combination (29).
In addition to AMPs, complement components also seem to
have an anti-tumoral action as it had been well documented that
leukemic cells have the ability to activate both alternative and lectin
pathways of complement. This activation leads to opsonization of
tumor cells and their subsequent uptake by NK cells and leukocytes
[reviewed in Ref. (30)].
ANTIMICROBIAL PEPTIDES AS NOVEL ANTI-TUMORAL
THERAPIES
Although a number of studies have demonstrated that some AMPs
exhibit anti-tumoral activity against different types of cancers such
as leukemia, ovarian, and prostate tumors; however, none of these
peptides are currently used commercially to target tumor cells. The
idea of using bacteria as anti-tumoral agents was first addressed
by two German scientists; W. Busch and F. Fehleisen. These two
physicians had individually noted that infections with Strepto-
coccus pyogenes in some cancer patients resulted in a regression
of tumor cells. However, the American physician William Coley
was the first to start a well-documented approach to use bacte-
ria in treatment of cancer back in 1890. Coley had managed to
develop a vaccine, which combined two killed bacterial species
and used it to treat lymphomas, sarcomas, melanomas, and myelo-
mas with a high success rate. In addition, some anaerobic bacteria
have been shown to selectively target solid tumors and leading
to tumor lysis. However, this approach was abandoned after the
introduction of radiation, chemotherapy, and surgery as standard
tools for cancer treatment. Side effects associated with these afore-
mentioned therapies or difficult locations of tumors have stressed
the need to look for novel therapies for cancer treatment, which
would either replace or supplement conventional cancer thera-
pies. Hence, the use of bacteria and AMPs in cancer treatment
has been taken up again. It is thought the cationic nature of the
AMPs enable them to interact with the various anionic molecules
such as sialic acid residues, heparan sulfate, and anionic phos-
phatidylserine, which are largely present on the surface of cancer
cells. This explains why AMPs are more prone to interact with
tumor rather than non-tumor cells. A number of in vitro and
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in vivo studies have given evidence on the anti-tumoral activ-
ity that some AMPs possess (31). Melittin is an AMP extracted
from the European honey bee Apis mellifera induces cell lysis.
A conjugate of melittin/avidin engineered to target cancer cells
with high matrix metalloproteinase 2 (MMP2) activities lead to
a significant decrease in the size of B16 tumor in mice (32). A
recent study has proposed using BD2 in immunogene therapy of
tumors. This strategy involves recruitment of immature dendritic
cells to the tumor microenvironment and subsequently promoting
their maturation, which will provoke a local anti-tumor immune
response (33).
Antimicrobial peptides are not selective against tumor cells.
Thus, further systemic investigations into these AMPs are needed
to understand the molecular properties, which make these pep-
tides appropriate for clinical use.
OUTLOOK
In conclusion, a number of studies have addressed the role of
AMP during carcinogeneis and cancer progression. But arrived
at contradictary conclusions with regard to anti-tumor or tumor
promoting activities, some groups have even suggested that cer-
tain AMP might provide an unconventional approach for cancer
treatment. In addition to complement components, there is good
evidence that certain AMP such as defensins and Cathelicidins
influence the mobilization from bone marrow and recruitment of
cells in the tumor microenvironment (34).
During inflammation, complement components C5a and C3a
are generated leading to chemoattraction of immune cells such
as T lymphocytes, monocytes, and eosinophils. Subsequently, the
interaction of these components with their receptors leads to
release of cytokines and reactive oxygen species resulting in tis-
sue damage. Persistent inflammation leads to the establishment
of a microenvironment supportive for tumor growth. Tumor-
mediated complement activation provides a continuous source
of complement activation bioactive products creating an inflam-
matory environment supporting tumor growth. It was found that
activation of C3aR and C5aR lead to an increase in expression
of IL-6 mRNA, which is a potent cytokine capable of stimulating
angiogenesis and inhibiting apoptosis in tumor cells (35).
Taken together, both complement components and some anti-
microbial peptides of the innate immune defense arm have a role
in regulating and trafficking of immune cells during tumorige-
nesis as well as in modulating the adaptive anti-tumor immune
response. Their direct role on tumor cells may be more distinct.
Therefore, future studies should attempt to study the role of these
two effector systems together rather than in isolation to uncover
the relative importance of each and possible additive, exploitable,
effects during carcinogeneis and cancer progression.
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